Investors

Half year liquidity contract statement

15 January 2021, Sophia Antipolis, France

Press Release – For immediate release – 05:45 pm CET

Half year liquidity contract statement

Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to Louis Capital Markets|Midcap Partners, the following resources were listed in the liquidity account as of 12/31/2020:

  • 35,698 shares
  • € 79,709.31 in cash

During the second half of 2020, it has been traded a total of:

BUY 180,188 Shares EUR 1,271,243.68 540 transactions
SELL 177,008 Shares EUR 1,276,566.46 461 transactions

It is recalled that at the time of the half-yearly statement of 06/30/2020, the following resources were included in the liquidity account:

  • 32,518 shares
  • € 77,124.37 in cash

It is recalled that when the new liquidity contract was put in place on 05/04/2020, the following resources were made available:

  • 4,404 shares
  • € 173,829.64 in cash

The daily transaction table is provided in the appendix to this press release.

In addition, please note that in connection with the acquisition of Louis Capital Markets|Midcap Partners by the TPICAP Plc group, the liquidity agreement previously held by Louis Capital Markets UK, LLP was automatically transferred on 12/31/2020 to TP ICAP (EUROPE), the French entity of the TPICAP group, authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median has received the “Innovative Company” label from BPI France, is eligible for the French SME equity savings plan scheme (PEA-PME), is listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.

Contacts

Median Technologies

Emmanuelle Leygues
Head of Corporate and Marketing Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Actifin  (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com